The Senate Health, Education, Labor & Pensions Committee last night voted 13-9 to advance legislation that would reauthorize Food and Drug Administration user fee programs and modify the regulatory framework for laboratory developed tests. AHA last week urged lawmakers to consider certain changes to the LDT provisions to ensure continued access to these critical tests.  
 
The House last week passed its own bill (H.R. 7667) to reauthorize FDA user fee programs, which does not include the LDT provisions. Among other provisions, the House bill would include drugs on the FDA’s shortages list in a pilot program to designate advanced manufacturing technologies. 
 

Related News Articles

Headline
The Senate Finance Committee last week released draft legislation to improve mental health parity and access to behavioral health services in Medicare and…
Headline
AHA today urged Congress to take certain steps to strengthen the behavioral health workforce, reduce regulatory burdens for psychiatric facilities, and revise…
Headline
In a letter yesterday, AHA and other national organizations urged congressional leaders to prevent the Statutory Pay-As-You-Go Act of 2010 sequester from…
Headline
The Workgroup for Electronic Data Interchange advisory group yesterday urged Health and Human Services Secretary Xavier Becerra to work closely with standards…
Perspective
After Election Day, lawmakers will return to Washington to consider many important issues, including funding the government, the annual must-pass defense bill…
Headline
At an AHA virtual policy briefing today for congressional staff, hospital and health system leaders urged Congress to prioritize actions to address the…